Oncology Care Model Measure Specifications

OCM-8 NQF 0223 Adjuvant chemotherapy is recommended or administered within 4 months (120 days) of diagnosis to patients under the age of 80 with AJCC III (lymph node positive) colon cancer

Note: This version of the OCM-8 Measure Specifications is to be used for reporting for the measurement period beginning 01/01/2018 and future measurement periods. If an updated version of this document is released, this version will be used for reporting until the effective date of the new version.

Note: This specification should be used for submitting data through the data registry

SUMMARY OF CHANGES FROM NQF 0223 SPECIFICATIONS

- Timing added: Primary tumors of the colon must start during the 12 months before the end of the measurement period.
- Timing added: The clinical trial must start before the start of or during the measurement period and not end before the start of the measurement period.
- Timing added: Chemotherapy must be recommended and not received within 4 months (120 days) of diagnosis.

Description
Percentage of patients under the age of 80 with AJCC III (lymph node positive) colon cancer for whom adjuvant chemotherapy is recommended and not received or administered within 4 months (120 days) of diagnosis.

Measure Scoring
Proportion

Measure Type
Process

Improvement Notation
Higher score indicates better quality

Definitions
Not Applicable

Guidance
This measure is to be reported once per measurement period for qualifying patients.

Where available, FORDS equivalent NAACCR Items have been provided in the step instructions of the supplemental data elements and each population.
Onology Care Model Measure Specifications

Chemotherapy recommended and not received:
1. Not recommended/administered because it was contraindicated due to patient risk factors.
2. Not administered because the patient died prior to planned or recommended therapy.
3. It was recommended by the patient’s physician but was not administered as part of the first course of therapy. No reason was stated in the patient record.
4. It was recommended by the patient’s physician but refused by the patient, patient’s family member, or the patient’s guardian. The refusal was noted in the patient record.

Supplemental Data Elements
For every patient evaluated by this measure also identify gender

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
</table>
| Step 1  | For every patient evaluated by this measure identify gender | • Gender  
(FORDS equivalent:  
NAACCR Item 220) | • OCM Gender  
OR  
• NAACCR Item 220 |

Initial Population
Not Applicable

Denominator
Include, if all of the following characteristics are identified:
• Age 18-79 years at time of cancer diagnosis
• Known or assumed to be first or only cancer diagnosis
• Primary tumors of the colon starts during the 12 months before the end of the measurement period
• Colon Cancer treated surgically
• Epithelial invasive malignancy only
• At least one pathologically examined regional lymph node positive for cancer (AJCC Stage III)
• All or part of first course of treatment coordinated by the reporting practice

Note: For beneficiary-level reporting, cancer diagnosis and AJCC values reported for Staging and Clinical Data in the OCM Data Registry will be used.
## Oncology Care Model Measure Specifications

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Step 1</strong></td>
<td>Age &gt;= 18 year(s) at time of colon cancer diagnosis AND Age &lt;= 79 year(s) at time of colon cancer diagnosis Note: NAACCR Items listed below may be used for practice-level aggregate reporting only. (FORDS equivalent: NAACCR Item 230) AND Primary tumors of the colon starts during the 12 months before the end of the measurement period: Note: NAACCR Items listed below may be used for practice-level aggregate reporting only. NAACCR Item 400 NAACCR Item 390</td>
<td>• Birthdate • Colon Cancer Diagnosis • Colon Cancer Diagnosis Start Date • Measurement Period End Date • NAACCR Item 230 • NAACCR Item 400 • NAACCR Item 390</td>
<td>• OCM Colon Cancer Diagnosis Additionally, for practice-level aggregate reporting: • NAACCR Item 230 • NAACCR Item 400 • NAACCR Item 390</td>
</tr>
<tr>
<td><strong>Step 2</strong></td>
<td>First or only cancer diagnosis Note: NAACCR Item listed below may be used for practice-level aggregate reporting only. (FORDS equivalent: NAACCR Item 560)</td>
<td>• Colon Cancer Diagnosis • Colon Cancer Diagnosis Start Date • Other Cancer Diagnosis • Other Cancer Diagnosis Start Date • NAACCR Item 560</td>
<td>• OCM Colon Cancer Diagnosis • OCM 8 Other Cancer Diagnosis Additionally, for practice-level aggregate reporting: • NAACCR Item 560</td>
</tr>
<tr>
<td><strong>Step 3</strong></td>
<td>Surgical treatment of the primary colon cancer site (FORDS equivalent: NAACCR Item 1290)</td>
<td>• Colon Cancer Surgery • Colon Cancer Surgery Date • NAACCR Item 1290</td>
<td>• OCM Colon Cancer Surgery OR • NAACCR Item 1290</td>
</tr>
<tr>
<td><strong>Step 4</strong></td>
<td>Epithelial invasive malignancy only (FORDS equivalent: NAACCR Item 522)</td>
<td>• Epithelial Malignancy • NAACCR Item 522</td>
<td>• OCM 8 Epithelial Malignancy OR • NAACCR Item 522</td>
</tr>
<tr>
<td><strong>Step 5</strong></td>
<td>Behavior Code=Invasive: NAACCR Item 523</td>
<td>• NAACCR Item 523</td>
<td>• NAACCR Item 523</td>
</tr>
</tbody>
</table>
### Step 6
At least one regional lymph node positive for cancer (AJCC Stage III)

Identify the valid TNM combinations using the following code sets:
- OCM 8 T values
- OCM 8 N values
- OCM 8 M values

Any combination of valid TNM values which correlate to AJCC Stage III (lymph node positive) colon cancer are allowed.

Note: Cancer stage and NAACCR Items listed below may be used for practice-level aggregate reporting only.

(FORDS equivalent:
- NAACCR Item 820)

OR

Pathology Staging Result

- Pathology Staging
- OCM 8 T values
- OCM 8 N values
- OCM 8 M values
- Pathology Staging Result
- NAACCR Item 820

One code from each of the following:
- OCM 8 T values
- OCM 8 N values
- OCM 8 M values

Additionally, for practice-level aggregate reporting:
- OCM Pathology Staging

AND

One of the following options:
1. NAACCR Item 820
   OR
2. OCM 8 Pathology Staging Result

### Step 7
All or part of first course of treatment coordinated by the reporting practice:

- NAACCR Item 610

### Denominator Exclusions
Exclude, if any of the following characteristics are identified:
- In situ or metastatic disease (AJCC Stage IV)
- Patient died within 4 months (120 days) of diagnosis
- Patient participating in clinical trial which directly impacts receipt of standard of care after the colon cancer diagnosis
## Oncology Care Model Measure Specifications

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
</table>
| **Step 1** | One of the following options: | • Colon Cancer Diagnosis  
• Colon Cancer Diagnosis Start Date  
• Deceased  
• Deceased Date  
• Clinical Trial Participant  
• Clinical Trial Participant Start Date  
• Clinical Trial Participant End Date  
• In Situ Diagnosis  
• Measurement Period Start Date  
• Measurement Period End Date  
• Metastatic Cancer Diagnosis  
• NAACCR Item 390  
• NAACCR Item 900  
• NAACCR Item 910 Metastatic  
• NAACCR Item 970  
• NAACCR Item 970 In Situ  
• OCM 8 Metastatic Cancer Diagnosis  
• OCM 8 In Situ Diagnosis  
• OCM Deceased  
• OCM Colon Cancer Diagnosis OR  
• NAACCR Item 1750 <120 days of diagnosis [NAACCR Item 390]  
• NAACCR Item 1750  
• NAACCR Item 1760  
| One of the following options: | 1. | • NAACCR Item 910 Metastatic  
• NAACCR Item 970 Metastatic  
• OCM 8 Metastatic Cancer Diagnosis  
| | 2. | • NAACCR Item 900  
• NAACCR Item 960  
| | 3. | • NAACCR Item 910 In Situ  
• NAACCR Item 970 In Situ  
• OCM 8 In Situ Diagnosis  
| | 4. | • OCM Deceased  
• OCM Colon Cancer Diagnosis OR  
| | 5. | • NAACCR Item 1760  
• NAACCR Item 1750  
| | 5. | • Clinical Trial Participant |

### Numerator

Chemotherapy is administered within 4 months (120 days) of diagnosis or it is recommended and not received within 4 months (120 days) of diagnosis
### Oncology Care Model Measure Specifications

<table>
<thead>
<tr>
<th>Step(s)</th>
<th>Instructions</th>
<th>Data Element(s)</th>
<th>OCM Code Set(s)</th>
</tr>
</thead>
</table>
| **Step 1** | Note: NAACCR Item 390 and 1220 listed below may be used for practice-level aggregate reporting only.  
One of the following options:  
1. Chemotherapy is administered within 4 months (120 days) of diagnosis  
   (All of the following FORDS equivalent:  
   • NAACCR Item 1390 Administered  
   • NAACCR Item 1220  
   • NAACCR Item 390)  
2. Chemotherapy is recommended and not received within 4 months (120 days) of diagnosis  
   (Both of the following FORDS equivalent:  
   • NAACCR Item 1390 Recommended  
   • NAACCR Item 390) | • Colon Cancer Diagnosis  
• Colon Cancer Diagnosis Start Date  
• Chemotherapy  
• Chemotherapy Start Date  
• Chemotherapy Recommended  
• Chemotherapy Recommended Start Date  
• NAACCR Item 1390 Administered  
• NAACCR Item 1390 Recommended  
• NAACCR Item 1220  
• NAACCR Item 390 | One of the following options:  
1. OCM Colon Cancer Diagnosis AND  
OCM 8 Chemotherapy OR  
• OCM Colon Cancer Diagnosis AND  
• NAACCR Item 1390 Administered  
2. OCM Colon Cancer Diagnosis AND  
OCM Chemotherapy Recommended OR  
• OCM Colon Cancer Diagnosis AND  
• NAACCR Item 1390 Recommended  
Additionally, for practice-level aggregate reporting:  
• NAACCR Item 390  
• NAACCR Item 1220 |

### Denominator Exceptions
Not Applicable

### Numerator Exclusions
Not Applicable

### Risk Adjustment
None
## Oncology Care Model Measure Specifications

**Rationale**
Improved survival for patients with Stage III lymph node positive colon cancer

**Clinical Recommendation Statements**
Not Applicable

**References**


**Copyright**
This measure is owned by the Commission on Cancer, American College of Surgeons.
Oncology Care Model Measure Specifications

Note: This version of the OCM-8 Measure Flow is to be used for reporting for the measurement period beginning 01/01/2018 and future measurement periods. If an updated version of this document is released, this version will be used for reporting until the effective date of the new version.

Start

Beneficiary-Level Reporting: Qualifying OCM FFS Beneficiary as Defined in Section 2.1 of the "OCM Clinical Data and Quality Measures Guide"

Aggregate-Level Reporting: Qualifying Practice-Level Patient with "Colon Cancer Diagnosis" Code (see "OCM Tech Spec Value Set" OCM-8 tab)

Denominator Met

Yes

Patient Age at Time of Colon Cancer Diagnosis ≥ 18 Years and ≤ 79 Years

No

Yes

Primary Tumors of the Colon Starts During 12 Months Before End of Measurement Period

No

All or Part of First Course of Treatment Coordinated by Reporting Practice

Yes

At Least One Regional Lymph Node Positive for Cancer (AJCC Stage III)

No

Behavior Code = Invasive

Yes

First or Only Cancer Diagnosis

No

Denominator Not Met

A

Surgical Treatment of Primary Colon Cancer Site

No

Epithelial Invasive Malignancy Only

Yes

Behavior Code = Invasive

No

Yes

Denominator Met
Chemotherapy Administered Within 4 Months (120 Days) of Diagnosis

Chemotherapy Recommended and Not Received Within 4 Months (120 Days) of Diagnosis

Expired Within 4 Months (120 Days) of Colon Cancer Diagnosis

Participating in Clinical Trial for Colon Cancer Impacting Treatment During Measurement Period

Denominator Exclusions Met

Denominator Exclusions Not Met

Numerator Not Met

Numerator Met

Stop Processing
Oncology Care Model Measure Specifications

Please refer to the OCM Measure Specification to identify the data elements and OCM code sets to be used for reporting this measure.

1. For Beneficiary-Level Reporting:
   a. If patient is a Qualifying OCM FFS Beneficiary as Defined in Section 2.1 of the “OCM Clinical Data and Quality Measures Guide,” patient should be reported in the OCM Registry. Proceed to check Patient Age.
   b. If patient is not a Qualifying OCM FFS Beneficiary as Defined in Section 2.1 of the “OCM Clinical Data and Quality Measures Guide,” stop processing. Patient does not qualify as an OCM FFS Beneficiary and patient-level data should not be reported to the OCM Registry.

2. For Aggregate-Level Reporting:
   a. If patient is a Qualifying Practice-Level Patient with “Colon Cancer Diagnosis” Code (see “OCM Tech Spec Value Set” OCM-8 tab), include the patient in aggregate-level totals for reporting to the OCM Registry. Proceed to check Patient Age.
   b. If patient is not a Qualifying Practice-Level Patient with “OCM Colon Cancer Diagnosis” Code (see “OCM Tech Spec Value Set” OCM-8 tab), stop processing. Patient does not qualify as a Practice-Level Patient and should not be included in aggregate-level totals that are reported to the OCM Registry.

3. Check Patient Age:
   a. If Patient Age at Time of Colon Cancer Diagnosis >= 18 Years and <= 79 Years equals No, do not include in Denominator. Stop processing.
   b. If Patient Age at Time of Colon Cancer Diagnosis >= 18 Years and <= 79 Years equals Yes, check Primary Tumors of the Colon.

4. Check Primary Tumors of the Colon:
   a. If Primary Tumors of the Colon Starts During 12 Months Before End of Measurement Period equals No, do not include in Denominator. Stop processing.
   b. If Primary Tumors of the Colon Starts During 12 Months Before End of Measurement Period equals Yes, check Patient Diagnosis of Cancer.

5. Check Patient Diagnosis of Cancer:
   a. If First or Only Cancer Diagnosis equals No, do not include in Denominator. Stop processing.
   b. If First or Only Cancer Diagnosis equals Yes, check Surgical Treatment.
Oncology Care Model Measure Specifications

6. Check Surgical Treatment:
   a. If Surgical Treatment of Primary Colon Cancer Site equals No, do not include in Denominator. Stop processing.
   b. If Surgical Treatment of Primary Colon Cancer Site equals Yes, check Epithelial Invasive Malignancy Only.

7. Check Epithelial Invasive Malignancy Only:
   a. If Epithelial Invasive Malignancy Only equals No, do not include in Denominator. Stop processing.
   b. If Epithelial Invasive Malignancy Only equals Yes, check Behavior Code.

8. Check Behavior Code:
   a. If Behavior Code = Invasive equals No, do not include in Denominator. Stop processing.
   b. If Behavior Code = Invasive equals Yes, check At Least One Regional Lymph Node Positive for Cancer.

9. Check At Least One Regional Lymph Node Positive for Cancer:
   a. If At Least One Regional Lymph Node Positive for Cancer (AJCC Stage III) equals No, do not include in Denominator. Stop processing.
   b. If At Least One Regional Lymph Node Positive for Cancer (AJCC Stage III) equals Yes, check First Course of Treatment.

10. Check First Course of Treatment:
    a. If All or Part of First Course of Treatment Coordinated by Reporting Practice equals No, do not include in Denominator. Stop processing.
    b. If All or Part of First Course of Treatment Coordinated by Reporting Practice equals Yes, include in Denominator. Proceed to check Metastatic Disease.

11. Check Metastatic Disease:
    a. If Metastatic Disease (AJCC Stage IV) equals Yes, include in Denominator Exclusions. Stop processing.
    b. If Metastatic Disease (AJCC Stage IV) equals No, check Clinical M or Pathologic M.

12. Check Clinical M or Pathologic M:
Oncology Care Model Measure Specifications

a. If Clinical M or Pathologic M equals Yes, include in Denominator Exclusions. Stop processing.

b. If Clinical M or Pathologic M equals No, check In Situ Disease.

13. Check In Situ Disease:

a. If In Situ Disease equals Yes, include in Denominator Exclusions. Stop processing.

b. If In Situ Disease equals No, check Patient Expired.

14. Check Patient Expired:

a. If Expired Within 4 Months (120 Days) of Colon Cancer Diagnosis equals Yes, include in Denominator Exclusions. Stop processing.

b. If Expired Within 4 Months (120 Days) of Colon Cancer Diagnosis equals No, check Participating in Clinical Trial.

15. Check Participating in Clinical Trial:

a. If Participating in Clinical Trial for Colon Cancer Impacting Treatment During Measurement Period equals Yes, include in Denominator Exclusions. Stop processing.

b. If Participating in Clinical Trial for Colon Cancer Impacting Treatment During Measurement Period equals No, do not include in Denominator Exclusions. Proceed to check Chemotherapy Administered.

16. Check Chemotherapy Administered:

a. If Chemotherapy Administered Within 4 Months (120 Days) of Diagnosis equals Yes, include in Numerator. Stop processing.

b. If Chemotherapy Administered Within 4 Months (120 Days) of Diagnosis equals No, check Chemotherapy Recommended and Not Received.

17. Check Chemotherapy Recommended and Not Received:

a. If Chemotherapy Recommended and Not Received Within 4 Months (120 Days) of Diagnosis equals Yes, include in Numerator. Stop processing.

b. If Chemotherapy Recommended and Not Received Within 4 Months (120 Days) of Diagnosis equals No, do not include in Numerator. Stop processing.